Investigating COVID-19 active pharmaceutical ingredients (APIs) degradation using Peroxydisulfate/FeMnOx binary metal oxide/Ultrasound System

Abstract

Degradation of Favipiravir using a hybrid system of peroxydisulfate, FeMnOx binary metal oxide, and ultrasound irradiation was studied. A novel catalyst was synthesized with deep eutectic solvent (DES). The effects of DES type on catalytic performance was evaluated and the catalysts were characterized using XRD, SEM, BET, XPS, and EDS. DES-based catalysts exhibited higher efficiency due to structure change, surface area enhancement and significantly improved Favipiravir adsorption. The DES-based catalyst exhibited a 30 % increase in surface area and a 20-fold increase in Mn content. Additionally, XRD and XPS analyses suggested the reduction of Fe3+ ions, possibly to Fe3O4. Optimal operational parameters (pH = 10, catalyst dose = 500 mg/L, and rox = 20) provide removal efficiency of 70.1 % after 3 h. The catalyst showed stable activity after three cycles, indicating reusability. This study presents a promising approach for the sustainable degradation of COVID-19 APIs, with implications for the pharmaceutical industry.

Keywords

• Binary metal oxide
• Advanced oxidation processes (AOPs)
• Wastewater treatment
• Radicals
• Cavitation
• Contaminants of emerging concern